On the heals of the DOJ’s recent tough stance against reverse payment suits, the EC has issued a major report on drug patent issues. Although it backs off tough earlier rhetoric against the industry and places some blame for delay on EU regulation, the Commission also cites patent suits and settlements as the cause of delay. Like the US enforcers, the EC has vowed to challenge settlements that it believes are delaying the entry of generic drugs into the market.